Avricore Health Inc. (AVCRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -583.26 Thousand CAD | 14.57% |
| 2022 | -809.85 Thousand CAD | 53.59% |
| 2021 | -1.74 Million CAD | -103.11% |
| 2020 | -859.15 Thousand CAD | 46.32% |
| 2019 | -1.6 Million CAD | 44.46% |
| 2018 | -2.88 Million CAD | -45.05% |
| 2017 | -1.98 Million CAD | 14.86% |
| 2016 | -2.33 Million CAD | -35.01% |
| 2015 | -1.72 Million CAD | -123.13% |
| 2014 | -774.63 Thousand CAD | -301.17% |
| 2013 | -193.09 Thousand CAD | 54.2% |
| 2012 | -421.56 Thousand CAD | 77.49% |
| 2011 | -1.87 Million CAD | 53.86% |
| 2010 | -4.05 Million CAD | -222.82% |
| 2009 | -1.25 Million CAD | 35.12% |
| 2008 | -1.93 Million CAD | -244.74% |
| 2007 | -562.09 Thousand CAD | -34.66% |
| 2006 | -417.4 Thousand CAD | 24.52% |
| 2005 | -553.02 Thousand CAD | -0.91% |
| 2004 | -548.06 Thousand CAD | -928.22% |
| 2003 | -53.3 Thousand CAD | 23.26% |
| 2002 | -69.45 Thousand CAD | -453.41% |
| 2001 | -12.55 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 370.78 Thousand CAD | -56.42% |
| 2024 Q1 | 164.74 Thousand CAD | 152.32% |
| 2023 Q2 | -282.18 Thousand CAD | -46.84% |
| 2023 Q4 | 65.29 Thousand CAD | 123.15% |
| 2023 Q3 | -281.99 Thousand CAD | 0.07% |
| 2023 FY | -691.84 Thousand CAD | 14.57% |
| 2023 Q1 | -192.18 Thousand CAD | 19.0% |
| 2022 FY | -809.85 Thousand CAD | 53.59% |
| 2022 Q1 | -185.57 Thousand CAD | 11.23% |
| 2022 Q2 | -207.36 Thousand CAD | -11.74% |
| 2022 Q3 | -179.67 Thousand CAD | 13.35% |
| 2022 Q4 | -237.24 Thousand CAD | -32.04% |
| 2021 Q2 | -344.3 Thousand CAD | 49.19% |
| 2021 FY | -1.74 Million CAD | -103.11% |
| 2021 Q3 | -438.55 Thousand CAD | -27.37% |
| 2021 Q4 | -209.06 Thousand CAD | 52.33% |
| 2021 Q1 | -677.61 Thousand CAD | -115.02% |
| 2020 FY | -859.15 Thousand CAD | 46.32% |
| 2020 Q4 | -315.13 Thousand CAD | -92.16% |
| 2020 Q3 | -163.99 Thousand CAD | 2.74% |
| 2020 Q2 | -168.6 Thousand CAD | 18.05% |
| 2020 Q1 | -205.74 Thousand CAD | 8.22% |
| 2019 FY | -1.6 Million CAD | 44.46% |
| 2019 Q3 | -366.92 Thousand CAD | 13.65% |
| 2019 Q2 | -424.94 Thousand CAD | 27.33% |
| 2019 Q1 | -584.77 Thousand CAD | 15.87% |
| 2019 Q4 | -224.17 Thousand CAD | 38.91% |
| 2018 FY | -2.88 Million CAD | -45.05% |
| 2018 Q4 | -695.1 Thousand CAD | 13.05% |
| 2018 Q3 | -799.47 Thousand CAD | -10.09% |
| 2018 Q2 | -726.19 Thousand CAD | -9.85% |
| 2018 Q1 | -661.06 Thousand CAD | 0.49% |
| 2017 Q3 | -551.59 Thousand CAD | -45.57% |
| 2017 FY | -1.98 Million CAD | 14.86% |
| 2017 Q1 | -391.96 Thousand CAD | 56.61% |
| 2017 Q2 | -378.93 Thousand CAD | 3.33% |
| 2017 Q4 | -664.35 Thousand CAD | -20.44% |
| 2016 Q1 | -712.05 Thousand CAD | -10.88% |
| 2016 FY | -2.33 Million CAD | -35.01% |
| 2016 Q2 | -403.9 Thousand CAD | 43.28% |
| 2016 Q4 | -903.35 Thousand CAD | -187.48% |
| 2016 Q3 | -314.23 Thousand CAD | 22.2% |
| 2015 FY | -1.72 Million CAD | -123.13% |
| 2015 Q4 | -642.19 Thousand CAD | -15.19% |
| 2015 Q1 | -460.75 Thousand CAD | -12.44% |
| 2015 Q2 | -696.96 Thousand CAD | -51.26% |
| 2015 Q3 | -557.52 Thousand CAD | 20.01% |
| 2014 Q3 | -157.6 Thousand CAD | 39.5% |
| 2014 Q2 | -260.5 Thousand CAD | -11.46% |
| 2014 Q1 | -233.71 Thousand CAD | -112.63% |
| 2014 FY | -774.63 Thousand CAD | -301.17% |
| 2014 Q4 | -409.78 Thousand CAD | -160.0% |
| 2013 Q3 | -169.03 Thousand CAD | -69.15% |
| 2013 Q1 | -34.88 Thousand CAD | -8.26% |
| 2013 Q2 | -99.93 Thousand CAD | -186.48% |
| 2013 Q4 | -109.91 Thousand CAD | 34.97% |
| 2013 FY | -193.09 Thousand CAD | 54.2% |
| 2012 FY | -421.56 Thousand CAD | 77.49% |
| 2012 Q2 | -124.11 Thousand CAD | -130.79% |
| 2012 Q3 | -26.06 Thousand CAD | 79.0% |
| 2012 Q4 | -32.22 Thousand CAD | -23.63% |
| 2012 Q1 | -53.77 Thousand CAD | 10.9% |
| 2011 Q1 | -262.71 Thousand CAD | 74.64% |
| 2011 FY | -1.87 Million CAD | 53.86% |
| 2011 Q3 | -180.25 Thousand CAD | 81.01% |
| 2011 Q4 | -60.35 Thousand CAD | 66.52% |
| 2011 Q2 | -949.05 Thousand CAD | -261.25% |
| 2010 Q2 | -1.28 Million CAD | 25.83% |
| 2010 Q3 | -333.95 Thousand CAD | 74.07% |
| 2010 Q1 | -1.73 Million CAD | -404.7% |
| 2010 Q4 | -1.03 Million CAD | -210.16% |
| 2010 FY | -4.05 Million CAD | -222.82% |
| 2009 Q1 | -238.07 Thousand CAD | 23.01% |
| 2009 Q2 | -444.22 Thousand CAD | -86.59% |
| 2009 Q3 | -691.36 Thousand CAD | -55.63% |
| 2009 Q4 | -344.06 Thousand CAD | 50.23% |
| 2009 FY | -1.25 Million CAD | 35.12% |
| 2008 FY | -1.93 Million CAD | -244.74% |
| 2008 Q4 | -309.23 Thousand CAD | -17.2% |
| 2008 Q3 | -263.86 Thousand CAD | 70.46% |
| 2008 Q2 | -893.34 Thousand CAD | -168.63% |
| 2008 Q1 | -332.55 Thousand CAD | 42.24% |
| 2007 Q3 | -136.07 Thousand CAD | 49.43% |
| 2007 Q2 | -269.09 Thousand CAD | -205.97% |
| 2007 Q1 | -87.94 Thousand CAD | 2.48% |
| 2007 Q4 | -575.76 Thousand CAD | -323.12% |
| 2007 FY | -562.09 Thousand CAD | -34.66% |
| 2006 Q4 | -90.18 Thousand CAD | 22.13% |
| 2006 Q1 | -118.42 Thousand CAD | 14.42% |
| 2006 Q2 | -67.38 Thousand CAD | 43.1% |
| 2006 Q3 | -115.81 Thousand CAD | -71.87% |
| 2006 FY | -417.4 Thousand CAD | 24.52% |
| 2005 Q1 | -134.8 Thousand CAD | 10.14% |
| 2005 Q2 | -127.63 Thousand CAD | 5.32% |
| 2005 Q3 | -130.61 Thousand CAD | -2.33% |
| 2005 Q4 | -138.37 Thousand CAD | -5.94% |
| 2005 FY | -553.02 Thousand CAD | -0.91% |
| 2004 FY | -548.06 Thousand CAD | -928.22% |
| 2004 Q4 | -150.01 Thousand CAD | -6.17% |
| 2004 Q3 | -141.29 Thousand CAD | 36.03% |
| 2004 Q2 | -220.89 Thousand CAD | -12.88% |
| 2004 Q1 | -195.69 Thousand CAD | -83.2% |
| 2003 Q1 | -11.5 Thousand CAD | 31.23% |
| 2003 Q4 | -106.82 Thousand CAD | -911.08% |
| 2003 Q3 | -10.56 Thousand CAD | 42.07% |
| 2003 FY | -53.3 Thousand CAD | 23.26% |
| 2003 Q2 | -18.23 Thousand CAD | -58.5% |
| 2002 Q4 | -16.73 Thousand CAD | -134.51% |
| 2002 FY | -69.45 Thousand CAD | -453.41% |
| 2002 Q3 | -7135.00 CAD | 0.0% |
| 2001 FY | -12.55 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 53.038% |
| Arrayit Corporation | -3.62 Million USD | 83.899% |
| Atlantic International Corp. | -5.73 Million USD | 89.825% |
| Biocept, Inc. | -31.98 Million USD | 98.176% |
| Bioqual, Inc. | -19.63 Thousand USD | -2870.089% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 24.461% |
| DermTech, Inc. | -103.73 Million USD | 99.438% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 100.023% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 97.2% |
| iMD Companies, Inc. | -175.44 Thousand USD | -232.448% |
| IDenta Corp. | -1499.00 USD | -38810.34% |
| Interpace Biosciences, Inc. | 2.8 Million USD | 120.801% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | 1607.537% |
| InVitro International | -25.33 Thousand USD | -2201.851% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 91.81% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | -903.693% |
| Medical Imaging Corp. | -819.48 Thousand USD | 28.825% |
| NovelStem International Corp. | -3.52 Million USD | 83.457% |
| Optigenex Inc. | 1.39 Million USD | 141.936% |
| PharmChem, Inc. | 973.14 Thousand USD | 159.936% |
| Proteome Sciences plc | -1.62 Million USD | 64.018% |
| Response Genetics, Inc | -21.37 Million USD | 97.272% |
| Rennova Health, Inc. | -1.4 Million USD | 58.62% |
| RushNet, Inc. | -684.7 Thousand USD | 14.815% |
| ScreenPro Security Inc. | -2.59 Million USD | 77.501% |
| Stella Diagnostics Inc. | -11.42 Million USD | 94.896% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 92.471% |
| Todos Medical Ltd. | -9.74 Million USD | 94.017% |